Laidlaw initiated coverage on IN8bio with a new price target
$INAB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Laidlaw initiated coverage of IN8bio with a rating of Buy and set a new price target of $7.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/18/2024 | $7.50 | Buy | Laidlaw |
| 8/30/2022 | $14.00 | Buy | H.C. Wainwright |
| 1/24/2022 | $19.00 → $9.00 | Buy | B. Riley Securities |
| 8/24/2021 | $12.00 | Buy | Mizuho |
| 8/23/2021 | $19.00 | Buy | B. Riley Securities |
8-K - IN8BIO, INC. (0001740279) (Filer)
8-K - IN8BIO, INC. (0001740279) (Filer)
8-K - IN8BIO, INC. (0001740279) (Filer)
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two yearsCompany to hos
100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year progression-free survival (PFS) and overall survival (OS), exceeding real-world control groups Patients treated with INB-100 demonstrating prolonged and durable remissions supported by gamma-delta T cell persistence beyond one year Company to host conference call at 8:30am EST today. Use this link to participate or access the listen-only version of the webcast here NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company devel
100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy. The Company will host a conference call at 4:15 pm ET. Use this link to participate. A listen-only version of the webcast is available here. NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clini
4 - IN8BIO, INC. (0001740279) (Issuer)
4 - IN8BIO, INC. (0001740279) (Issuer)
4 - IN8BIO, INC. (0001740279) (Issuer)
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two yearsCompany to hos
Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γδ T cells (Vδ1+ and Vδ2+), overcoming one of the critical challenges in patients with chronic disease and dysfunctional immune systems, low γδ T cell levels Broad Therapeutic Potential and Potential for Safer Treatments: The data suggest INB-619 can uniquely deliver deep immune clearance without trig
Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio's proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced new data on its proprietary γδ T manufacturing program. The o
Laidlaw initiated coverage of IN8bio with a rating of Buy and set a new price target of $7.50
H.C. Wainwright initiated coverage of IN8bio with a rating of Buy and set a new price target of $14.00
B. Riley Securities reiterated coverage of IN8bio with a rating of Buy and set a new price target of $9.00 from $19.00 previously
Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist with deep experience at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute (NCI), Goldman Sachs and most recently CARGO Therapeutics NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors. "Dr. Epperly brings an incredible range of ex
Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly's oncology portfolioHe is a highly respected industry leader in oncology with a track record of success in advancing multiple novel anti-cancer compounds into and through the clinic and has been instrumental in garnering the approval of several oncology products NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is pleased to announce the appointment of Jeremy Graff, Ph.D., to its Board of Directors
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board (SAB). Dr. Bishop is Director, Hematopoietic Cellular Therapy Program, and Director of the David and Etta Jonas Center for Cellular Therapy, and Professor of Medicine at the University of Chicago. He joins the other world-renowned experts in oncology, cellular immunotherapy and immunology on IN8bio's SAB who provide expertise, contribute insights and advise the Comp
SC 13D/A - IN8BIO, INC. (0001740279) (Subject)
SC 13G - IN8BIO, INC. (0001740279) (Subject)
SC 13G/A - IN8BIO, INC. (0001740279) (Subject)